CaMKIIδ gene editing- A base hit for the heart

Affiliations

Comment

Christopher J Walkey et al. J Cardiovasc Aging. 2023.

. 2023;3(2):19.

doi: 10.20517/jca.2023.11. Epub 2023 Mar 22.

¹ Department of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.

No abstract available

Keywords: Base editing; aav; crispr; heart; ischemia-reperfusion.

Conflict of interest statement

Conflicts of interests Both authors declared that there are no conflicts of interest.

Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease.
Lebek S, Chemello F, Caravia XM, Tan W, Li H, Chen K, Xu L, Liu N, Bassel-Duby R, Olson EN. Lebek S, et al. Science. 2023 Jan 13;379(6628):179-185. doi: 10.1126/science.ade1105. Epub 2023 Jan 12. Science. 2023. PMID: 36634166 Free PMC article.

1. Lebek S, Chemello F, Caravia XM. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science 2023;379:179–85. - PMC - PubMed
1. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013;123:92–100. - PMC - PubMed
1. He BJ, Joiner ML, Singh MV, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med 2011;17:1610–8. - PMC - PubMed
1. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005;11:409–17. - PubMed
1. van Oort RJ, McCauley MD, Dixit SS, et al. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 2010;122:2669–79. - PMC - PubMed